Richard P Slaughter Associates Inc Abb Vie Inc. Transaction History

Richard P Slaughter Associates Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 11, 2022	SELL	$131.98 - $163.75 $3 Million - $3.72 Million	-22,714 Closed	0 $0
Q4 2021 Jan 13, 2022	BUY	$107.43 - $135.93 $44,690 - $56,546	416 Added 1.87%	22,714 $3.08 Million
Q3 2021 Oct 06, 2021	SELL	$106.4 - $120.78 $158,642 - $180,082	-1,491 Reduced 6.27%	22,298 $2.41 Million
Q2 2021 Jul 12, 2021	BUY	$105.21 - $117.21 $32,615 - $36,335	310 Added 1.32%	23,789 $2.68 Million
Q1 2021 Apr 14, 2021	SELL	$102.3 - $112.62 $379,533 - $417,820	-3,710 Reduced 13.65%	23,479 $2.54 Million
Q4 2020 Jan 20, 2021	BUY	$80.49 - $108.67 $11,268 - $15,213	140 Added 0.52%	27,189 $2.91 Million
Q3 2020 Oct 13, 2020	BUY	$85.91 - $100.83 $98,968 - $116,156	1,152 Added 4.45%	27,049 $2.37 Million
Q2 2020 Jul 09, 2020	SELL	$73.37 - $98.18 $379,836 - $508,277	-5,177 Reduced 16.66%	25,897 $2.54 Million
Q1 2020 May 28, 2020	BUY	$64.5 - $97.79 $132,483 - $200,860	2,054 Added 7.08%	31,074 $2.37 Million
Q4 2019 May 27, 2020	BUY	$72.13 - $90.25 $2.09 Million - $2.62 Million	29,020 New	29,020 $2.57 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Richard P Slaughter Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Richard P Slaughter Associates Inc with notifications on news.